TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34412908
Drug: Anastrozole 1
Normalized name: anastrozole 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole 1 mg daily until progression or unacceptable toxicity
Study: 32881765
Drug: TXA (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXA (2 g) administered prior to hospital arrival, less than 2 hours postinjury.
Study: 32881765
Drug: TXA (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXA (2 g) administered less than 45 minutes postinjury.
Study: 32881765
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered prior to hospital arrival, less than 2 hours postinjury.
Study: 32840126
Drug: Reishi &
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reishi & Privet Formula (RPF) 3.36 g/day for 6 weeks
Study: 34538272
Drug: SELFIE (digital
Approvals — FDA: no, EMA: no, PMDA: no
Description: SELFIE (digital guided self-help intervention administered through a smartphone-based app, blended with three training sessions over a 6-week period)
Study: 33200214
Drug: ACTsmart intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACTsmart intervention (guided smartphone-delivered Acceptance and Commitment Therapy) for 8 weeks
Study: 32956694
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg estetrol / 3 mg drospirenone (E4/DRSP)
Study: 32956694
Drug: 30 mcg
Normalized name: Avonex 30 MCG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mcg ethinylestradiol / 150 mcg levonorgestrel (EE/LNG)
Study: 32956694
Drug: 20 mcg
Normalized name: Caverject 20 MCG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mcg ethinylestradiol / 3 mg drospirenone (EE/DRSP)
Study: 34143278
Drug: CORDIS (body-focused
Approvals — FDA: no, EMA: no, PMDA: no
Description: CORDIS (body-focused group therapy)
Study: 34889742
Drug: Face-to-face Cognitive
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face-to-face Cognitive Behavioral Therapy (FTF-CBT)
Study: 35316669
Drug: Mood stabilizer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mood stabilizer combined with antidepressant
Study: 34441942
Drug: Peripheral parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral parenteral nutrition (PPN) with Peri‐Olimel N4‐E
Study: 34441942
Drug: Conventional fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional fluid therapy (FT)
Study: 35138529
Drug: Afatinib monotherapy
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Afatinib monotherapy
Study: 35029238
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of afatinib and HAD-B1
Study: 34970203
Drug: Zonisamide (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zonisamide (25 mg per day) before bedtime for 28 days
Study: 34889293
Drug: Moxibustion therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxibustion therapy (3 sessions per week for 8 weeks)
Study: 32265057
Drug: VB-111 and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: VB-111 and paclitaxel (therapeutic dose 80 mg/m2)
Study: 32265057
Drug: VB-111 and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: VB-111 and paclitaxel (therapeutic dose)
Study: 32265057
Drug: Sub-therapeutic dose
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sub-therapeutic dose of VB-111 and paclitaxel
Study: 35758878
Drug: ALVAC/gp120 +
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALVAC/gp120 + MF59 vaccines
Study: 35734671
Drug: 600 μg
Normalized name: P.G. 600 KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 μg misoprostol
Study: 35734671
Drug: 800 μg
Normalized name: hyaluronidase
DrugBank: Hyaluronidase (DB14740)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 800 μg misoprostol vs 400 μg misoprostol
Study: 35734671
Drug: Higher misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher misoprostol dosage
Study: 34503644
Drug: Ciprofloxacin hydrochloride
Normalized name: Ciprofloxacin Hydrochloride
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin hydrochloride 250 mg (test product)
Study: 34503644
Drug: Ciprofloxacin hydrochloride
Normalized name: Ciprofloxacin Hydrochloride
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin hydrochloride 250 mg (reference product)
Study: 33158415
Drug: High carbon
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High carbon and nitrogen metabolism in the liver.
Study: 33216667
Drug: Closed-loop control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-loop control (CLC) insulin delivery system
Study: 35060542
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (FA) tablets 0.8 mg and oral levamlodipine besylate 2.5 mg, once a day for 12 weeks, followed by adjusted FA dose for another 12 weeks
Study: 35060542
Drug: Oral levamlodipine
Normalized name: Levamlodipine
DrugBank: Levamlodipine (DB09237)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral levamlodipine besylate tablets 2.5 mg and placebo, once a day
Study: 33377285
Drug: MP-gel applied
Normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MP-gel applied as SCT (short contact therapy) once daily (evening application) with complete removal after 1 hour using a gentle cleanser
Study: 33377285
Drug: MP-gel used
Normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MP-gel used as SAT (standard application therapy) once daily (evening application)
Study: 33871486
Drug: Light curing
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light curing 120 seconds after cement injection (SG3)
Study: 33871486
Drug: Light curing
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light curing 20 seconds after cement injection (SG2)
Study: 33413744
Drug: TQLB with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQLB with 0.6 ml/kg of 0.5% ropivacaine plus general anesthesia
Study: 36060955
Drug: Empagliflozin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin (10 mg once or two times daily) with metformin
Study: 36060955
Drug: Vildagliptin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin (50 mg once or two times daily) with metformin
Study: 32721919
Drug: Desmopressin acetate
Normalized name: Desmopressin Acetate
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Desmopressin acetate (DDAVP) 0.3 ug/kg, administered 30 min once a day after surgery
Study: 32721919
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (saline 50 ml for 30 min)
Study: 32419114
Drug: Psychosocial treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychosocial treatments emphasizing learning skills and strategies (82.5% preference among parents)
Study: 32419114
Drug: Involvement of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Involvement of parents in treatment (96.8% preference among parents)
Study: 36856733
Drug: Peptide receptor
Normalized name: Polypeptide receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peptide receptor radionuclide therapy
Study: 32632880
Drug: Various systemic
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various systemic medical therapies
Study: 35701830
Drug: Oral naproxen
Normalized name: naproxen Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral naproxen 500 mg twice daily for 10 days
Study: 32303041
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral group therapy (work‐coping group WG)
Study: 33548897
Drug: Aprepitant (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant (320 mg)
Study: 34425320
Drug: Healthy diet
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy diet supplemented with 30 mL/d of extra virgin olive oil (OOG)
Study: 34425320
Drug: Healthy diet
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy diet supplemented with 30 g/d of pecans (PNG)
Study: 33296484
Drug: Combination group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination group (Ultrasound-guided technique + Nerve Stimulator)
Study: 34232000
Drug: PLLA reconstituted
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLLA reconstituted with 8 mL sterile water for injection (SWFI) including 1 mL 2% lidocaine
Study: 34232000
Drug: PLLA reconstituted
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLLA reconstituted with 5 mL sterile water for injection (SWFI)
Study: 33121980
Drug: Pitolisant (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitolisant (titrated individually at up to 20 mg/day for 12 weeks)
Study: 32474426
Drug: Target-specific anticancer
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target-specific anticancer drugs
Study: 34851251
Drug: Ularitide as
Normalized name: Ularitide
DrugBank: Ularitide (DB05034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ularitide as a continuous intravenous infusion during hospitalisation as an add-on to any diuretic treatment
Study: 34851251
Drug: Placebo as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo as a continuous intravenous infusion during hospitalisation as an add-on to any diuretic treatment
Study: 616741974
Drug: Low-dose group
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose group (1850 MBq)
Study: 36204963
Drug: Immediate implantation
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate implantation group (17 implants)
Study: 36204963
Drug: Delayed implantation
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed implantation group (19 implants)
Study: 35730535
Drug: Dual use
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual use of oral tobacco-derived nicotine (OTDN) products (VERVE chews/discs)
Study: 32251026
Drug: anti-inflammatory drugs
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-inflammatory drugs
Study: 32251026
Drug: neuroprotective drugs
Normalized name: NEUROPROTECTIN D1
DrugBank: AP-001 (DB18511)
Approvals — FDA: no, EMA: no, PMDA: no
Description: neuroprotective drugs
Study: 32883555
Drug: Trivalent GBS
Normalized name: GB-13
DrugBank: GB-13 (DB18387)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent GBS vaccine
Study: 36323243
Drug: AM‐301 (bentonite
Approvals — FDA: no, EMA: no, PMDA: no
Description: AM‐301 (bentonite nasal spray)
Study: 36323243
Drug: HPMC (Nasaleze®
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPMC (Nasaleze® Allergy Blocker)
Study: 34759146
Drug: High-dose Methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Methotrexate (HD-MTX) continued-maintenance therapy (3.5g/m2)
Study: 33586819
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavioural therapy programme without additional videoconference sessions
Study: 33586819
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavioural therapy programme with additional videoconference sessions
Study: 34786956
Drug: Tanezumab 5
Normalized name: tanezumab
DrugBank: Tanezumab (DB12335)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tanezumab 5 mg every 8 weeks
Study: 34786956
Drug: Tanezumab 10
Normalized name: tanezumab
DrugBank: Tanezumab (DB12335)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tanezumab 10 mg every 8 weeks
Study: 34052118
Drug: Self-help relaxation
Normalized name: endothelium-derived relaxing factor
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-help relaxation exercise twice per day for 4 weeks
Study: 34261371
Drug: Flurbiprofen 8.75
Normalized name: flurbiprofen 8.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen 8.75 mg lozenges
Study: 33665685
Drug: Ertugliflozin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertugliflozin (5 mg or 15 mg)
Study: 32966714
Drug: Ertugliflozin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertugliflozin (5 mg)
Study: 32966714
Drug: Ertugliflozin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertugliflozin (15 mg)
Study: 33599809
Drug: 0.4-g/kg dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4-g/kg dose of alcohol
Study: 33245582
Drug: CD34+ cell
Normalized name: CD34+ Cells
DrugBank: Autologous peripheral blood-derived CD34+ cells (DB16367)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD34+ cell count >32 × 10^6/L
Study: 34366890
Drug: Whole-body electromyostimulation
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-body electromyostimulation (WB-EMS) for 20 min once weekly (n = 27)
Study: 35544171
Drug: Antidepressant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant treatment group
Study: 33933665
Drug: ML digital
Approvals — FDA: no, EMA: no, PMDA: no
Description: ML digital support platform (PRESTO) with a smartphone app for monitoring and delivering psychological interventions for anxiety and depressive symptoms.
Study: 33933665
Drug: ML predictive
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: ML predictive severity model based on cases referred to the PC mental health support programme.
Study: 35381686
Drug: Aspirin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (100 mg daily for 14 days)
Study: 35381686
Drug: Cilostazol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol (200 mg daily for 14 days)
Study: 34227198
Drug: 30 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g/day milled flaxseed
Study: 34227198
Drug: 30 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g/day milled rice
Study: 32436794
Drug: 1 mL
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL of a 2% lidocaine–0.5% bupivacaine mixture
Study: 32436794
Drug: 2 mL
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL of a 2% lidocaine–0.5% bupivacaine mixture
Study: 32436794
Drug: 3 mL
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mL of a 2% lidocaine–0.5% bupivacaine mixture
Study: 34322703
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus low-dose cytarabine
Study: 34260795
Drug: Apararenone 10
Normalized name: Apararenone
DrugBank: Apararenone (DB15024)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apararenone 10 mg/day
Study: 36483140
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment control (DT)
Study: 36316102
Drug: Rilonacept monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilonacept monotherapy
Study: 36316102
Drug: Rilonacept monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilonacept monotherapy (sequential taper)
Study: 36316102
Drug: Rilonacept monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilonacept monotherapy (concurrent taper)
Study: 36316102
Drug: Rilonacept monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilonacept monotherapy (low glucocorticoid dose)
Study: 36316102
Drug: Rilonacept monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilonacept monotherapy (high glucocorticoid dose)
Study: 36316102
Drug: Rilonacept monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilonacept monotherapy (long-term glucocorticoid use)
Study: 36369609
Drug: Test preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test preparation (T) 10 mg
Study: 36369609
Drug: Reference preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference preparation (R) 10 mg
Study: 36369609
Drug: Both T
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both T and R preparations
Study: 33296841
Drug: Current best
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current best oral replacement regime (suboptimal circadian and ultradian rhythm)
Study: 34794198
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of TXA and DXM (Group D)
Study: 33646727
Drug: Laughter therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laughter therapy (twice a week for 6 weeks)
Study: 36415901
Drug: Immediate intensive
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate intensive periodontal therapy
Study: 36415901
Drug: Delayed therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed therapy (control group)
Study: 35026408
Drug: Extended-release Quetiapine
Normalized name: quetiapine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release Quetiapine
Study: 35026408
Drug: Aripiprazole or
Normalized name: aripiprazole Oral Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole or Extended-release Quetiapine
Study: 34806452
Drug: 12.5% dextrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5% dextrose water (DW) serum, 8.75 to 18.75 g/kg/d
Study: 34806452
Drug: 10% dextrose
Normalized name: Aminosyn II 4.25% in 10% Dextrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% dextrose water (DW) serum, 7 to 15 g/kg/d
Study: 32620149
Drug: Physical activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical activity program with connected devices (activity tracker worn 24/7, at least three weekly walking sessions, quizzes on physical activity and nutrition) for 6 months
Study: 33389132
Drug: 2/W‐TPTD (28.2‐μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2/W‐TPTD (28.2‐μg teriparatide formulation for twice‐weekly use)
Study: 33389132
Drug: 1/W‐TPTD (56.5‐μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1/W‐TPTD (56.5‐μg teriparatide formulation for once‐weekly use)
Study: 35953409
Drug: Preoperative lanreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative lanreotide (120 mg)
Study: 34362859
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and Commitment Therapy (ACT), ten 50‐minute weekly sessions
Study: 36147279
Drug: Topical cyclosporin
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cyclosporin A (CsA) 0.05% for 3 months
Study: 32152146
Drug: Genistein capsules
DrugBank: Genistein (DB01645)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genistein capsules (50 mg/day) for 2 months
Study: 35841024
Drug: Virtual Intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Virtual Intervention Treatment (VIT) - includes up to 11 virtual counseling sessions with a tobacco treatment specialist and up to 12 weeks of nicotine replacement therapy (NRT)
Study: 34704720
Drug: Placebo subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo subcutaneous injection
Study: 35840999
Drug: 12-month pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-month pantoprazole treatment arm
Study: 35840999
Drug: 1-month pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-month pantoprazole treatment arm
Study: 32891281
Drug: Yogic meditation
Normalized name: benzalkonium chloride Topical Foam [Meditize]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yogic meditation (MG) for eight weeks
Study: 33313724
Drug: Physical Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical Therapy (PT) for 6 weeks
Study: 33313724
Drug: Army Medicine's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Army Medicine's holistic Move2Health (M2H) program for 6 weeks
Study: 33665728
Drug: WM (bioequivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: WM (bioequivalent formulation)
Study: 32151851
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker
Study: 34755388
Drug: Bayesian group-sequential
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bayesian group-sequential trial design utilizing Multisource Exchangeability Models
Study: 34755388
Drug: Traditional group-sequential
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional group-sequential design
Study: 32404056
Drug: 2 L‐PEG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 L‐PEG solutions with 1 L GT liquids
Study: 32404056
Drug: 2 L‐PEG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 L‐PEG solutions only
Study: 34732695
Drug: Overt SSRI
Normalized name: Wal-vert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overt SSRI treatment with escitalopram 20 mg
Study: 34732695
Drug: Covert SSRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Covert SSRI treatment with escitalopram 20 mg
Study: 34732695
Drug: Overt SSRI
Normalized name: Wal-vert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overt SSRI treatment
Study: 34732695
Drug: Covert SSRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Covert SSRI treatment
Study: 32041601
Drug: Ensifentrine 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ensifentrine 0.75 mg
Study: 32041601
Drug: Ensifentrine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ensifentrine 1.5 mg
Study: 32041601
Drug: Ensifentrine 3
Normalized name: ENSIFENTRINE 3MG/2.5ML INHL SUSP AMP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ensifentrine 3 mg
Study: 32041601
Drug: Ensifentrine 6
Normalized name: Ensifentrine
DrugBank: Ensifentrine (DB16157)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ensifentrine 6 mg
Study: 32041601
Drug: Ensifentrine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ensifentrine (all doses)
Study: 32885518
Drug: Reminiscence therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reminiscence therapy (RT) intervention
Study: 33499668
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy with rate/rhythm control agents